Halozyme Therapeutics logo
Halozyme Therapeutics HALO
$ 64.29 0.99%

Annual report 2025
added 02-17-2026

report update icon

Halozyme Therapeutics Net Debt 2011-2026 | HALO

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Halozyme Therapeutics

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
1.27 B 758 M 646 M 282 M 68.4 M 33.6 M 150 M 6.54 M 62.7 M 66.6 M -68.8 M -52.8 M

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
1.27 B -68.8 M 269 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
AbCellera Biologics AbCellera Biologics
ABCL
14.7 M $ 3.56 2.01 % $ 1.06 B canadaCanada
Acorda Therapeutics Acorda Therapeutics
ACOR
114 M - -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
-27.4 M - 4.01 % $ 150 M canadaCanada
Advaxis Advaxis
ADXS
3.42 M - -9.65 % $ 45.9 M usaUSA
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
-2.77 M $ 0.79 -0.79 % $ 4.31 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
Albireo Pharma Albireo Pharma
ALBO
-239 M - -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-3.44 M - 10.36 % $ 9.8 M usaUSA
argenx SE argenx SE
ARGX
-89.9 M $ 703.3 0.41 % $ 25 B niderlandNiderland
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
-195 M $ 231.03 2.23 % $ 5 B danmarkDanmark
ADC Therapeutics SA ADC Therapeutics SA
ADCT
-459 M $ 4.22 2.18 % $ 105 M schweizSchweiz
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
-34.7 M $ 3.61 0.28 % $ 8.69 B australiaAustralia
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
31.1 M - - $ 86.2 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
-56.5 M - - $ 10.1 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
-206 M $ 6.63 -0.75 % $ 182 M israelIsrael
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA
Athersys Athersys
ATHX
-27.6 M - 3.77 % $ 22.4 M usaUSA
Akouos Akouos
AKUS
-92.9 M - 0.23 % $ 488 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
-2.08 M - 2.71 % $ 14 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
-60.6 M - 1052.0 % $ 415 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-29.5 M - 3.16 % $ 1.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-65.1 M - 5.93 % $ 314 M canadaCanada
AlloVir AlloVir
ALVR
-62.7 M - 4.14 % $ 49.1 M usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
-46 M $ 14.36 1.13 % $ 210 M usaUSA
Aptinyx Aptinyx
APTX
-33.8 M - -39.0 % $ 4.57 M usaUSA
BioNTech SE BioNTech SE
BNTX
-973 M $ 90.54 -0.71 % $ 27.2 B germanyGermany
Aptose Biosciences Aptose Biosciences
APTO
-5.53 M - -45.71 % $ 1.2 M canadaCanada
Burford Capital Limited Burford Capital Limited
BUR
-135 M $ 8.05 1.64 % $ 1.31 B britainBritain
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
-48 M - - $ 521 M usaUSA
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
-63.1 M $ 6.05 -0.82 % $ 493 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-657 K - - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
-19.9 M $ 2.64 3.94 % $ 16.6 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
-3.13 K - -52.27 % $ 4.45 M usaUSA
BioCardia BioCardia
BCDA
212 K $ 1.27 0.79 % $ 26.9 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-187 M $ 1.51 4.86 % $ 385 M britainBritain
Athira Pharma Athira Pharma
ATHA
-47.2 M - - $ 269 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
-3.5 M $ 3.58 -0.56 % $ 7.79 B israelIsrael
CureVac N.V. CureVac N.V.
CVAC
-783 M - - $ 867 M germanyGermany
Aravive Aravive
ARAV
-49.6 M - -13.39 % $ 1.45 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
9.86 B - - $ 96.9 B britainBritain
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
-72.3 M $ 1.11 - $ 33.4 M usaUSA